Charles Ching

Biography

Charles Ching
Charles Ching is a partner in the Corporate Department and heads the Firm’s China practice. He represents financial sponsors and corporate clients on cross-border M&A and investment transactions, with particular focus on private equity investments in China-based businesses, outbound M&A by Chinese buyers, and regional joint ventures and other corporate transactions. He regularly advises China-based clients on some of the most complex and noteworthy public and private M&A transactions in the United States and globally, having practiced previously in New York and Hong Kong.

Mr. Ching is recognized as a leading transactional lawyer by Chambers Asia-Pacific and Legal 500, and is cited as a “Highly Regarded” lawyer for M&A in China by IFLR1000. Chambers noted him for his ability to “find a commercially-balanced solution in complicated situations” and for his “fully attentive and responsive approach”. IFLR1000 referred to him as a “strong communicator, commercially-minded, knowledgeable about the law, responsive/easy to track down.”

Mr. Ching is included in China Business Law Journal’s annual “A-List” for 2018 and 2019 as one of the leading 100 lawyers in foreign firms in China. In addition, he is named in The Best Lawyers™ in China 2020 and further earned the distinction of 2020 Private Equity and Venture Capital “Lawyer of the Year” in Shanghai.

Mr. Ching’s recent representations include:

  • SoftBank Vision Fund in the $2 billion investment in Coupang, one of South Korea’s largest online retailers
  • Warburg Pincus in multiple matters, including (1) the investment in Sichuan Jinxin Fertility, one of China’s leading assisted reproduction healthcare providers, (2) the joint venture with a life sciences company, (3) the investment in Hong Kong-listed Franshion Properties and Mingfa Group, two large real estate developers in China and (4) various China healthcare investments including Hygeia, Evercare and Amcare
  • Advent International in multiple matters, including (1) the acquisition of Best Learning, an English language training institute for juniors in China and (2) the acquisition of a majority stake in King Koil Shanghai Sleep System, a leading, premium manufacturer and retailer of mattresses in China, from CITIC Capital
  • Shanghai Pharmaceuticals on the $1.2 billion acquisition of U.S.-based Cardinal Health’s pharmaceutical and medical products distribution business in China
  • Oaktree Capital on the sale of the Axilone business to CITIC Capital
  • Primavera Capital in multiple matters, including (1) the investment in Local Services Holding, one of China’s leading digital services platforms, (2) the investment in Kuaishou Technology, a provider of internet media services, as part of Kuaishou’s Series E equity funding round led by Tencent Holding and (3) the investment in Koubei, an on-demand local services platform in China, as part of Koubei’s $1.1 billion equity financing round
  • A sovereign wealth fund in an investment in TutorGroup Co Ltd., an online provider of education services in China
  • HNA Group in multiple matters, including (1) the $6.5 billion acquisition of a 25% stake in Hilton Inc., Park Hotels & Resorts Inc. and Hilton Grand Vacations Inc. (collectively, formerly known as Hilton Worldwide Holdings) from Blackstone and (2) in connection with the $6 billion acquisition of U.S.-listed Ingram Micro, an IT logistics and solutions provider, with Tianjin Tianhai Investment Company
  • Hillhouse Capital in multiple matters, including as an investor in Mogujie.com, a large fashion-focused e-commerce service in China, and in Meilishuo.com, an online women’s apparel retailer, in the $3 billion merger of equals of Mogujie.com and Meilishuo.com
  • A technology fund investing in Bytedance, a leading Chinese internet conglomerate
  • Avolon Holdings, an aircraft leasing and management services provider, on the $7.6 billion acquisition of the company by Bohai Leasing
  • Boquan He, as a member of a consortium, in the $1.1 billion take-private of iKang Healthcare Group, one of the largest providers of preventative healthcare services in China
  • Apple in the investment in DiDi Chuxing, and in DiDi Chuxing’s acquisition of Uber (China) Ltd.

Mr. Ching is qualified in New York and Hong Kong. He is a native Mandarin speaker.

Firm News & Announcements, Awards and Recognition, Speaking Engagements, Guides and Resources, Latest Thinking

Firm News & Announcements

View all

Awards and Recognition